ProMining Therapeutics and Roche have collaborated for the discovery of small molecule therapeutics against type 2 diabetes mellitus.
According to the deal, ProMining will use its CavitIIRx platform in the discovery programme and will receive research based funding.
The technology aids in discovering small molecules interfering in protein-protein interactions that are differentiated from usual small molecule drugs.
ProMining CEO Dr. Iris Alroy said, "This partnership will enable ProMining to expand the exploitation of this technology by combining with the impressive global research and development capabilities and resources of Roche."
Additional details of the deal were not revealed.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/promining-roche-collaborate-on-type-2-diabetes-research-181212
